BioCryst Pharmaceuticals Stock Options
| BCRX Stock | USD 7.45 0.39 5.52% |
BioCryst Pharmaceuticals' latest option contracts expiring on March 21st 2025 are carrying combined implied volatility of 0.95 with a put-to-call open interest ratio of 0.5 over 22 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on March 21st 2025. The total put volume is at 30.0, with calls trading at the volume of 7.0. This yields a 4.29 put-to-call volume ratio.
Open Interest Against March 21st 2025 Option Contracts
BioCryst Pharmaceuticals option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in BioCryst Pharmaceuticals' lending market. For example, when BioCryst Pharmaceuticals' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on BioCryst Pharmaceuticals, he or she must hedge the risk by shorting BioCryst Pharmaceuticals stock over its option's life.
2025-03-21
The chart above shows BioCryst Pharmaceuticals' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. BioCryst Pharmaceuticals' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for BioCryst Pharmaceuticals' option, there is no secondary market available for investors to trade.
BioCryst Pharmaceuticals Maximum Pain Price Across 2025-03-21 Option Contracts
Max pain occurs when BioCryst Pharmaceuticals' market makers reach a net positive position across all BioCryst Pharmaceuticals' options at a strike price where option holders stand to lose the most money. By contrast, BioCryst Pharmaceuticals' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on BioCryst Pharmaceuticals
Analyzing BioCryst Pharmaceuticals' in-the-money options over time can help investors to take a profitable long position in BioCryst Pharmaceuticals regardless of its overall volatility. This is especially true when BioCryst Pharmaceuticals' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money BioCryst Pharmaceuticals' options could be used as guardians of the underlying stock as they move almost dollar for dollar with BioCryst Pharmaceuticals' stock while costing only a fraction of its price.
BioCryst Pharmaceuticals In The Money Call Balance
When BioCryst Pharmaceuticals' strike price is surpassing the current stock price, the option contract against BioCryst Pharmaceuticals stock is said to be in the money. When it comes to buying BioCryst Pharmaceuticals' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on BioCryst Pharmaceuticals are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
BioCryst Current Options Market Mood
BioCryst Pharmaceuticals' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps BioCryst Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most BioCryst Pharmaceuticals' options investors are not very successful. BioCryst Pharmaceuticals' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current BioCryst contract
Base on the Rule 16, the options market is currently suggesting that BioCryst Pharmaceuticals will have an average daily up or down price movement of about 0.0594% per day over the life of the 2025-03-21 option contract. With BioCryst Pharmaceuticals trading at USD 7.45, that is roughly USD 0.004423. If you think that the market is fully incorporating BioCryst Pharmaceuticals' daily price movement you should consider buying BioCryst Pharmaceuticals options at the current volatility level of 0.95%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
BioCryst |
Purchasing BioCryst Pharmaceuticals options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" BioCryst calls. Remember, the seller must deliver BioCryst Pharmaceuticals stock to the call owner when a call is exercised.
BioCryst Pharmaceuticals Option Chain
When BioCryst Pharmaceuticals' strike price is surpassing the current stock price, the option contract against BioCryst Pharmaceuticals stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
BioCryst Pharmaceuticals' option chain is a display of a range of information that helps investors for ways to trade options on BioCryst. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for BioCryst. It also shows strike prices and maturity days for a BioCryst Pharmaceuticals against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | BCRX250321C00004000 | 5 | 4.0 | 3.1 - 3.8 | 3.7 | In |
Call | BCRX250321C00005000 | 14 | 5.0 | 2.1 - 2.95 | 3.38 | In |
Call | BCRX250321C00006000 | 5 | 6.0 | 1.2 - 2.05 | 1.41 | In |
Call | BCRX250321C00007000 | 231 | 7.0 | 0.8 - 0.95 | 0.85 | In |
Call | BCRX250321C00008000 | 364 | 8.0 | 0.3 - 0.45 | 0.25 | Out |
Call | BCRX250321C00009000 | 180 | 9.0 | 0.0 - 0.3 | 0.25 | Out |
Call | BCRX250321C00010000 | 316 | 10.0 | 0.05 - 0.1 | 0.1 | Out |
Call | BCRX250321C00011000 | 20 | 11.0 | 0.0 - 0.55 | 0.15 | Out |
Call | BCRX250321C00012000 | 14 | 12.0 | 0.0 - 0.75 | 0.05 | Out |
Call | BCRX250321C00013000 | 1 | 13.0 | 0.0 - 0.75 | 0.12 | Out |
Call | BCRX250321C00014000 | 0 | 14.0 | 0.0 - 0.75 | 0.75 | |
Call | BCRX250321C00015000 | 7 | 15.0 | 0.0 - 0.25 | 0.15 | Out |
Put | BCRX250321P00006000 | 1 | 6.0 | 0.0 - 0.55 | 0.57 | Out |
Put | BCRX250321P00007000 | 203 | 7.0 | 0.3 - 0.45 | 0.35 | Out |
Put | BCRX250321P00008000 | 122 | 8.0 | 0.8 - 1.05 | 0.95 | In |
Put | BCRX250321P00009000 | 248 | 9.0 | 1.5 - 1.85 | 1.2 | In |
Put | BCRX250321P00010000 | 0 | 10.0 | 1.0 - 3.0 | 1.0 | In |
Put | BCRX250321P00011000 | 2 | 11.0 | 1.65 - 4.0 | 3.0 | In |
Put | BCRX250321P00012000 | 0 | 12.0 | 3.7 - 6.2 | 3.7 | In |
Put | BCRX250321P00013000 | 0 | 13.0 | 4.6 - 6.0 | 4.6 | In |
Put | BCRX250321P00014000 | 0 | 14.0 | 5.8 - 8.4 | 5.8 | In |
Put | BCRX250321P00015000 | 0 | 15.0 | 5.7 - 8.1 | 5.7 | In |
BioCryst Pharmaceuticals Selling And Marketing Expenses Over Time
Selling And Marketing Expenses |
| Timeline |
BioCryst Total Stockholder Equity
Total Stockholder Equity |
|
BioCryst Pharmaceuticals Corporate Management
| Yarlagadda Babu | Sr. VP of Drug Discovery | Profile | |
| Alane Barnes | VP, General Counsel and Corporate Secretary | Profile | |
| Elliott Berger | VP Affairs | Profile | |
| William MBBS | Chief Officer | Profile | |
| Stephanie Angelini | Chief Officer | Profile | |
| Michael Jones | Executive Officer | Profile | |
| Clayton Fletcher | Chief Officer | Profile |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.